Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
Abstract Number: 672 • 2018 ACR/ARHP Annual Meeting
Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
Seong-Kyu Kim¹ and Jung-Yoon Choe², ¹Rheumatology, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), ²Department of Internal Medicine, Catholic university of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: NLRP3 inflammasome is a molecular platform triggering activation of inflammatory cytokines including interleukin-1b (IL-1b). This study aimed to assess the expression of NLRP3 inflammasome…
Abstract Number: 1384 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
W. Benjamin Nowell¹, Regan Reynolds¹, Kelly Gavigan¹, Shilpa Venkatachalam¹, Marie de la Cruz², Emuella Flood², Ethan Schwartz², Beverly Romero², Yujin Park³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²ICON, Gaithersburg, MD, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily the sacroiliac joints and spine and can cause irreversible damage. Measuring disease…
Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Désirée van der Heijde¹, James Cheng-Chung Wei², Maxime Dougados³, Philip J. Mease⁴, Atul A. Deodhar⁵, Walter P. Maksymowych⁶, Filip van Den Bosch⁷, Joachim Sieper⁸, Tetsuya Tomita⁹, Robert B.M. Landewé¹⁰, Lotus Mallbris¹¹, Fangyi Zhao¹¹, David Adams¹¹, Beth Pangallo¹¹ and Hilde Carlier¹¹, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Oregon Health & Science U, Portland, OR, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁸Charité University Hospital, Berlin, Germany, ⁹Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁰Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
Abstract Number: 673 • 2018 ACR/ARHP Annual Meeting
Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
John D. Reveille¹, MinJae Lee², Laura A. Diekman³, Michael Ward⁴, Lianne S. Gensler⁵, Amirali Tahanan², Mohammad H. Rahbar⁶ and Michael Weisman⁷, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁴National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Harbor UCLA Medical Center, Los Angeles, CA
Background/Purpose: We examined first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) patients with chronic inflammatory back pain (CIBP), non-inflammatory CBP (NICBP) and no…
Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Christian Dejaco¹, Thomas Mueller², Omid Zamani, MD³, Ulrike Kurtz, MD⁴, Stefan Egger, MD⁵, Johannes Resch Passini, MD⁶, Anna Totzauer, MD⁷, Wolfgang Eisterer⁸, Babak Yazdani-Biuki, MD, Univ.Doc.⁹, Thomas Schwingenschloegl, MD¹⁰, Peter Peichl, MD. Univ.Doc. Msc¹¹, Angelika Kraus¹², Gerhard Naerr, PhD¹³ and Verena Rickert, MD. MBA¹⁴, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Private Office Dr. Thomas Mueller, Graz, Austria, ³Rheuma Zentrum Favoriten, Vienna, Austria, ⁴Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, ⁵Ordination Gesundheitsquadrat, Vienna, Austria, ⁶Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, ⁷Private Office Dr. Anna Totzauer, Gmuend, Austria, ⁸Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, ⁹Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, ¹⁰Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, ¹¹Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, ¹²Private Office, Private Office Angelika Kraus, Melk, Austria, ¹³Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, ¹⁴Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
Abstract Number: 1869 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Karel Pavelka², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Yi Wang⁷, Brian Porter⁸, Anna Stefanska⁹, Susanne Rohrer¹⁰ and Hanno Richards¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²1st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o.,, Uherske Hradiste, Czech Republic, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Ireland Limited, Dublin, Ireland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 3 study, which…
Abstract Number: 677 • 2018 ACR/ARHP Annual Meeting
Structural Damage Characteristics of Patients with Ankylosing Spondylitis in China
Weiping Kong¹, Caroline Jefferies², Thomas Learch³, Jinrui Cui⁴, Xiaowei Gan¹, Nan Zhang¹, Yingze Zhang¹, Jianming Wang¹, Qingwen Tao¹, Xiaoping Yan¹, Michael Weisman⁵ and Mariko Ishimori⁶, ¹China-Japan Friendship Hospital, Beijing, China, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Radiology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Harbor UCLA Medical Center, Los Angeles, CA, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Structural damage is a major cause of poor outcomes in patients with ankylosing spondylitis (AS). In China, structural damage characteristics of AS are rarely…
Abstract Number: 1517 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Arthur Kavanaugh¹, Atul A. Deodhar², Sergio Schwartzman³, Shelly Kafka⁴, Soumya D Chakravarty⁵, Elizabeth C Hsia⁶, Diane D. Harrison⁷, Jocelyn Leu⁷, Yiying Zhou⁷, Kim Hung Lo⁷ and M. Elaine Husni⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Oregon Health & Science U, Portland, OR, ³Weill Cornell Medical College, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁶Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid…
Abstract Number: 2066 • 2018 ACR/ARHP Annual Meeting
Serum IL-37 Is an Efficient Biomarker of Disease Activity and Treatment Response in Patients with Ankylosing Spondylitis
Ga Young Ahn¹, Su Man Kang², Juyeon Kang¹, Bora Nam¹, Hyuk-Hee Kwon¹, Tae-Hwan Kim³ and Dae-Hyun Yoo¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Institute of Rheumatology, Hanyang University, Seoul, Korea, Republic of (South), ³Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The measurement of disease activity is mainly dependent on the patient-reported outcome measures in ankylosing spondylitis (AS) patients. Current inflammatory biomarkers have insufficient sensitivity…
Abstract Number: 678 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Shahla Vahidfar¹, Ismihan Sunar², Sebnem Ataman³, Gürkan Yılmaz⁴, Javid M. AZARABADI⁵ and Ayşe Bölükbaşı¹, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Division of Rheumatology,, Ankara University, Faculty of Medicine, Ankara, Turkey, ³Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ⁴Physical Medicine and Rehabilitation, Rheumatology Division, Ankara University Faculty of Medicine, Ankara, Turkey, ⁵ORTHOPEDICS AND TRAUMATOLOGY, Başkent University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues…
Abstract Number: 1594 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Elevation in Patients with Ankylosing Spondylitis Treated with TNF Inhibitor: A Single-Center Historical Cohort Study
Su Jin Choi, Ji Seon Oh, Seokchan Hong, Yong-Gil Kim, Chang Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: TNF inhibitors have been known to cause liver enzyme elevation in rheumatologic disease. However, liver enzyme elevation could be affected easily by other causes…
Abstract Number: 2067 • 2018 ACR/ARHP Annual Meeting
Dysbiosis-Dependent Inflammasomes Activation Drives Innate Immune Responses in Ankylosing Spondylitis Patients
Francesco Ciccia¹, Giuliana Guggino¹, Aroldo Rizzo², Stefania Raimondo³, Simon Milling⁴ and Riccardo Alessandro³, ¹Rheumatology Unit, University of Palermo, Palermo, Italy, ²Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy, ³University of Palermo, Palermo, Italy, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: A growing body of evidences indicate that the aberrant activation of innate immune systems, occurring in genetically predisposed patients, drives inflammatory processes in Ankylosing…
Abstract Number: PP12 • 2018 ACR/ARHP Annual Meeting
Living a Full Life with A.S. Through Adaptations
Gail Wright, Spondylitis Association of America, Buffalo Grove, IL
Background/Diagnosis: After running a half marathon and 2 5’ks, I had unexplained back/ hip pain that wouldn’t resolve. I returned to my PT. After 3…
Abstract Number: 682 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Jean Liew¹, John D. Reveille², Michael Ward³, MinJae Lee⁴, Matthew Brown⁵, Mohammad H. Rahbar⁶, Michael Weisman⁷ and Lianne S. Gensler⁸, ¹Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ³National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁴Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, USA, Los Angeles, CA, ⁸University of California San Francisco, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in Ankylosing Spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line pharmacological therapy in AS; however, their…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].